Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
meeting symbols : Alny save search
Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023
Published: 2023-11-13 (Crawled : 14:30) - biospace.com/
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 1.02%
H: 4.5%
C: 3.38%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.04%
H: 1.92%
C: 1.89%
meeting hepatitis liver ongoing trials today
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023
Published: 2023-11-10 (Crawled : 15:00) - biospace.com/
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 0.98%
H: 7.06%
C: 6.93%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.49%
H: 0.74%
C: -2.08%
meeting hepatitis liver ongoing trials
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
Published: 2023-10-11 (Crawled : 12:00) - globenewswire.com
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: -0.9%
H: 2.27%
C: 0.68%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -1.16%
H: 1.43%
C: 0.43%
meeting hepatitis liver presentation
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-09-13 (Crawled : 22:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -1.8%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: 0.0%
fda positive treatment meeting
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-06-30 (Crawled : 14:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.94%
H: 0.0%
C: 0.0%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 1.45%
H: 1.03%
C: -2.01%
onpattro fda treatment meeting
Alnylam to Present Additional Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the Heart Failure Society of America Annual Scientific Meeting 2022
Published: 2022-09-13 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 1.78%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.97%
H: 0.16%
C: -0.98%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -1.77%
H: 0.54%
C: -0.8%
america meeting heart study
Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting
Published: 2022-01-14 (Crawled : 12:30) - biospace.com/
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 1.47%
H: 0.0%
C: 0.0%
results phase 3
New Results from Phase 1 Study of Cemdisiran + Pozelimab Presented at ASH Annual Meeting 2021
Published: 2021-12-14 (Crawled : 03:00) - alnylam.com
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 6.02%
H: 2.03%
C: -0.29%
phase 1 results phase 2 phase 3
New Long-Term Results for GIVLAARI® (givosiran) Presented at ASH Annual Meeting & Exposition
Published: 2021-12-13 (Crawled : 00:00) - alnylam.com
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 6.02%
H: 2.03%
C: -0.29%
givlaari results
New Results from ATLAS Phase 3 Program with Fitusiran Presented at ASH Annual Meeting 2021
Published: 2021-12-12 (Crawled : 20:20) - alnylam.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 3.01%
H: 0.28%
C: -2.39%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 2.8%
H: 0.0%
C: 0.0%
results phase 3
Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly
Published: 2021-11-12 (Crawled : 14:00) - biospace.com/
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -2.06%
H: 0.0%
C: 0.0%
preclinical collaboration research license pre-clinical
Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021
Published: 2021-11-12 (Crawled : 14:00) - biospace.com/
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -2.06%
H: 0.0%
C: 0.0%
disease liver disease phase 1 liver trial
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection at AASLD The Liver Meeting®
Published: 2021-11-12 (Crawled : 13:15) - globenewswire.com
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 4.66%
H: 0.0%
C: 0.0%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -2.06%
H: 0.0%
C: 0.0%
hepatitis potential biotech technology iot liver injection infections chronic hepatitis b
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2021
Published: 2021-10-15 (Crawled : 14:00) - biospace.com/
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: -0.02%
H: 3.08%
C: -2.81%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.34%
H: 0.09%
C: -0.69%
presentation hepatitis biotech technology iot liver
Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of the Oligonucleotides Therapeutics Society
Published: 2021-09-29 (Crawled : 12:15) - biospace.com/
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.82%
H: 2.31%
C: -0.6%
leo
RNAi Therapeutics Platform Progress at OTS 2021 Annual Meeting
Published: 2021-09-29 (Crawled : 12:00) - alnylam.com
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.82%
H: 2.31%
C: -0.6%
platform therapeutics
New Results from the OXLUMO® (lumasiran) Clinical Program Presented at AUA Annual Meeting
Published: 2021-09-10 (Crawled : 18:00) - alnylam.com
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.43%
H: 1.06%
C: -0.46%
results
New Results for Vutrisiran at EU-ATTR Amyloidosis Meeting
Published: 2021-09-07 (Crawled : 14:00) - alnylam.com
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: -4.76%
results
Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis Meeting
Published: 2021-09-07 (Crawled : 12:00) - biospace.com/
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: -4.76%
europe phase 3
Alnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual Meeting
Published: 2021-06-07 (Crawled : 12:00) - biospace.com/
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.19%
H: 3.41%
C: 3.14%
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.